Gynecologists and estrogen: An affair of the heart

Perspectives in Biology and Medicine

Volumn 49, Issue 1, 2006, Pages 115-130

  Fugh Berman, Adriane ^a   Scialli, Anthony R ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sciences International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CULTURAL FACTOR; ESTROGEN THERAPY; GYNECOLOGY; HEALTH BEHAVIOR; HEALTH PROMOTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; MENOPAUSE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SUBSTITUTION THERAPY;

CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; GYNECOLOGY; HEALTH PROMOTION; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS;

EID: 32444444270     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2006.0006     Document Type: Review

References (54)

1. American College of Obstetricians and Gynecologists (ACOG). 1992. Hormone replacement therapy. Technical bulletin no. 166. Washington, D.C.: ACOG.
2. American College of Obstetricians and Gynecologists (ACOG). 1998. Hormone replacement therapy. Educational bulletin no. 247. Washington, D.C.: ACOG.
3. Barrett-Connor, E. 1991. Postmenopausal estrogen and prevention bias. Ann Intern Med 115(6):455-56.
4. Berga, S. 2002. Comment on Speroff. WHI trial arm with E/P finds an increase in breast cancer. Ob-Gyn Clinical Alert 19(4):28-29.
5. Cherry, N., et al. 2002. Oestrogen therapy for prevention of reinfarction in postmenopausal women: A randomised placebo controlled trial. Lancet 360(9350):2001-8.
6. Collier, J., and I. Iheanacho. 2002. The pharmaceutical industry as an informant. Lancet 360:1405-9.
7. Contemporary Ob-Gyn. 2002. WHI and HRT (Dec.):77-101.
8. Cushman, M., et al. 2004. Estrogen plus progestin and risk of venous thrombosis. JAMA 292:1573-80.
9. Egeland, G. M., et al. 1988. Characteristics of noncontraceptive hormone users. Prev Med 17(4):403-11.
10. Ena, G., and S. Rozenberg. 2003. Issues to debate on the Women's Health Initiative (WHI) study: Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study. Hum Reprod 18(11):2245-48.
11. Ettinger, B., A. Pressman, and P. Silver. 1999. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 6(4):282-89.
12. Exline, J. L., I. C. Siegler, and L. A. Bastian. 1998. Differences in providers' beliefs about benefits and risks of hormone replacement therapy in managed care. J Women's Health 7(7):879-84.
13. Faulkner, D. L., et al. 1998. Patient noncompliance with hormone replacement therapy: A nationwide estimate using a large prescription claims database. Menopause 5(4):226-29.
14. Frank, E., and L. Elon. 2003. Clinical and personal relationships between oral contraceptive and hormone replacement therapy use among U.S. women physicians. Menopause 10(2):133-41.
15. Froom, P., et al. 1999. Healthy volunteer effect in industrial workers. J Clin Epidemiol 52 (8):731-35.
16. Grady, D., et al. 2002.Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288(1):49-57.
17. Grimes, D. A., and R. A. Lobo. 2002. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet Gynecol 100(6):1344-53.
18. Hays, J., et al. 2003. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348(19):1839-54.
19. Hemminki, E. 2004. Opposition to unpopular research results: Finnish professional reactions to the WHI findings. Health Policy 69(3):283-91.
20. Hemminki, E., et al. 1988. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86. Am J Public Health 78(11):1479-81.
21. Herrington, D. M., et al. 2000. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343(8):522-29.
22. Hersh, A. L., M. L. Stefanick, and R. S. Stafford. 2002. National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 291(1):47-53.
23. Hodis, H. N. 2002. Estrogen and atherosclerosis. Female Patient (Dec. suppl):2-4. Supplement was distributed as "A CME Enduring Material jointly sponsored by the Dannemiller Memorial Educational Foundation and Quadrant HealthCom Inc. Supported by an unrestricted educational grant from Pfizer Inc."
24. Hulley, S., et al. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280(7):605-13.
25. Isaacs, D., and D. Fitzgerald. 1999. Seven alternatives to evidence based medicine. BMJ 319(7225):1618.
26. Kaplan, B., et al. 2002. Gynecologists' trends and attitudes toward prescribing hormone replacement therapy during menopause. Menopause 9(5):354-59.
27. Kopernik, G., and Z. Shoham. 2004. Tools for making correct decisions regarding hormone therapy. Part II. Organ response and clinical applications. Fertil Steril 81(6): 1458-77.
28. Kritz-Silverstein, D., and E. Barrett-Connor. 1996. Long-term postmenopausal hormone use, obesity, and fat distribution in older women. JAMA 275(1):46-49.
29. Levy, B. T., et al. 2003. Physician specialty is significantly associated with hormone replacement therapy use. Obstet Gynecol 101(1):114-22.
30. Lindsted, K. D., et al. 1996. Healthy volunteer effect in a cohort study: Temporal resolution in the Adventist Health Study. J Clin Epidemiol 49(7):783-90.
31. Majumdar, S. R., E. A. Almasi, and R. S. Stafford. 2004. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 292 (16):1983-88.
32. Manson, J. E., et al. (Women's Health Initiative Investigators). 2003. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349(6):523-34.
33. McNagny, S. E., N. K. Wenger, and E. Frank. 1997. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States. Ann Intern Med 127(12):1093-96.
34. Naftolin, F, et al. 2004. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 81(6):1498-1501.
35. Olatunbosun, O. A., L. Edouard, and R. A. Pierson. 1998. Physicians' attitudes toward evidence based obstetric practice: A questionnaire survey. BMJ 316(7128):365-66.
36. Rolnick, S. J., et al. 1999. Provider attitudes and self-reported behaviors related to hormone replacement therapy. Menopause 6(3):257-63.
37. Rozenberg, S., C. Fellemans, and H. Ham. 2001. Opinion survey towards hormone replacement therapy in the prevention of coronary heart disease. Maturitas 38(3):273-77.
38. Salamone, L. M., et al. 1996. Estrogen replacement therapy. A survey of older women's attitudes. Arch Intern Med 156(12):1293-97.
39. Saver, B. G., et al. 1997. Physician policies on the use of preventive hormone therapy. Am J Prev Med 13(5):358-65.
40. Schulman, S. P., et al. 2002. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol 39(2):231-37.
41. Shoham, Z., and G. Kopernik. 2004. Tools for making correct decisions regarding hormone therapy. Part I. Background and drugs. Fertil Steril 81:1447-57.
42. Shumaker, S.A., et al. 2004. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291(24):2947-58.
43. Speroff, L. 2002a. Response to the WHI by clinicians. Ob-Gyn Clinical Alert 19(8):57-59.
44. Speroff, L. 2002b. Postmenopausal hormone therapy: A response to the critics. Ob-Gyn Clinical Alert 19(2):9-11.
45. Speroff, L. 2003. The WHI and quality of life. Ob-Gyn Clinical Alert 20(1):1-2.
46. Stafford, R. S., et al. 1997. Low rates of hormone replacement in visits to United States primary care physicians. Am J Obstet Gynecol 177(2):381-87.
47. Stamler, J. 1977. The coronary drug project: Findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol 82:52-75.
48. Stumpf, P. G, and M. P. Trolice. 1994. Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am 21(2):219-29.
49. Thorneycroft, I. 2001. The HERS trial does not confute a cardioprotective effect of hormone therapy. Menopause Management 10(4):16-28.
50. Utian, W. H. 1987. The fate of the untreated menopause. Obstet Gynecol Clin North Am 14(1):1-11.
51. Viscoli, C. M., et al. 2002. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 346(12):942-43.
52. Wilson, R. A. 1966. Feminine forever. New York: M. Evans.
53. Writing Group for the Women's Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3):321-33.
54. Zeldow, P. B., and S. R. Daugherty. 1991. Personality profiles and specialty choices of students from two medical school classes. Acad Med 66:283-87.